Cantor Fitzgerald set a neutral rating on Merck & Co., Inc. on September 12, 2026.
1 report, 1 independent
Updated Sep 12
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cantor Fitzgerald set a neutral rating on Merck & Co., Inc. on September 12, 2026.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Cantor Fitzgerald
American financial services company
Related events
- Cantor Fitzgerald began coverage and issued rating, and Morgan Stanley upgraded price objective and rating for Silence Therapeutics.
- Berenberg Bank reaffirmed a buy rating and Cantor Fitzgerald reissued a neutral rating on September 8, 2026.
- Cantor Fitzgerald raised its price target and rating, while Bank of America adjusted its rating and price target, with MarketBeat aggregating the stock rating data.
- Cantor Fitzgerald raised its price target and rating for Supernus Pharmaceuticals, Inc. on September 2, 2026, and the company filed a disclosure with the SEC.
- Cantor Fitzgerald restated an overweight rating on shares, while J. Goldman & Co LP purchased a new stake in Annexon. Disclosure was made to the Securities and Exchange Commission.